Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Safety Measures for Incretin-Related Drugs Insufficient: Medwatcher Japan
January 17, 2011
- HSB's Cancer-Related Budget Up ¥2.7 Bil. to ¥34.3 Bil. in FY2011
January 17, 2011
- Korosho Requires Thorough Explanations on OTC Cold Medicines before Sale
January 17, 2011
- Korosho to Require More Data Electronically on Clinical Trials
January 17, 2011
- WAKAMOTO Launches Vitreous Surgery Adjuvant MaQaid
January 17, 2011
- Tasigna Approved in 1st-Line Therapy for CML: Novartis
January 17, 2011
- Perpetuation of New Premium Top-Priority Issue in 2011: FPMAJ President Shoda
January 17, 2011
- FDA Grants Supplemental Approval for Roche's Actemra
January 17, 2011
- Shionogi Licenses NF-κB Decoy Oligo from AnGes MG
January 10, 2011
- Pharmarise to Increase Sales in Home Healthcare Business
January 10, 2011
- National Medical Expenditure Up 2% to ¥34,808.4 Bil.
January 10, 2011
- BMS Licenses Festinavir from Oncolys
January 10, 2011
- Signatures from 2.7 Mil. People Presented Demanding Expansion of Vaccination Programs
January 10, 2011
- Bristol-Myers, Otsuka Starts Copromoting Sprycel in Japan
January 10, 2011
- JRIA Hosts Seminar for Promoting Benefits of RI Treatment
January 10, 2011
- Eisai to Markets Analgesic Poultice in China
January 10, 2011
- FDA Warns Yuki Gosei Kogyo against CGMP Violations
January 10, 2011
- Takeda Settles with 11 US Generic Firms Regarding Generics of Actos
January 10, 2011
- Memantine's Package Insert to Include No Precaution on Coadministration with Aricept
January 10, 2011
- Barclays Revises MTPC's Business Forecasts Upward
January 10, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…